Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CASP2 | P42575 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | ECE1 | P42892 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10477936 | 0.88 | MEN1 (0.70) | MEN1KMT2AALDH1A1CASP2RECQL | |
| SCHEMBL24326890 | 0.86 | MEN1 (0.74) | MEN1KMT2AALDH1A1CASP2RECQL | |
| SCHEMBL14077543 | 0.85 | MEN1 (0.71) | MEN1KMT2AALDH1A1CASP2NAAA | |
| SCHEMBL14086343 | 0.85 | MEN1 (0.71) | MEN1KMT2AALDH1A1CASP2NAAA | |
| SCHEMBL7769416 | 0.84 | CASP2 (0.57) | MEN1KMT2AALDH1A1CASP2NAAA | |
| SCHEMBL11202755 | 0.82 | MEN1 (0.54) | MEN1KMT2AALDH1A1CASP2RECQL | |
| SCHEMBL20646379 | 0.82 | MEN1 (0.54) | MEN1KMT2AALDH1A1CASP2RECQL | |
| SCHEMBL14086285 | 0.81 | MEN1 (0.65) | MEN1KMT2ACASP2NAAATSHR | |
| SCHEMBL1418983 | 0.80 | CASP2 (0.53) | CASP2NAAAFAAH | |
| SCHEMBL22863842 | 0.80 | MEN1 (0.47) | MEN1KMT2AALDH1A1RECQLTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016029146-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON (US) | 2016-02-25 | — | — | WO | claimed |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | UNIVERSITY OF WASHINGTON (US) | 2021-02-09 | — | — | US | disclosed |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON | 2017-09-28 | — | — | US | disclosed |
| US-8293714-B2 | Anti-angiogenic compounds | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2012-10-23 | — | — | US | disclosed |
| US-20100003267-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LIMITED | 2010-01-07 | — | — | US | disclosed |
| EP-0757682-B1 | BENZOFURAN DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-06-20 | — | — | EP | disclosed |
| US-5858995-A | ADMINISTERING TO HUMANS AND ANIMALS IN THE TREATMENT OF DISEASES CAUSED BY ABNORMAL BONE METABOLISM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-01-12 | — | — | US | disclosed |
| EP-0757682-A1 | BENZOFURAN DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-12 | — | — | EP | disclosed |
| WO-1996034866-A1 | IMIDAZO 1,2-A PYRIDINE AND IMIDAZO 1,2-A PYRIDEZINE DERIVATIVES AND THEIR USE AS BONE RESORPTION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-11-07 | — | — | WO | disclosed |
| WO-1995029907-A1 | BENZOFURAN DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-11-09 | — | — | WO | disclosed |
| US-5453363-A | Solubilizing, reducing, and denaturing refractile bodies; oxidation with glutathione; genetic engineering | BOEHRINGER MANNHEIM GMBH (DE) | 1995-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003267-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, FLT1 | MEN1 3298/4885KMT2A 4489/4885ALDH1A1 2575/4885 |
| US-20170275279-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | AARS1, MTR, GARS1 | MEN1 2418/4885KMT2A 1195/4885ALDH1A1 2330/4885 |
| US-10913736-B2 | Specific inhibitors of methionyl-tRNA synthetase | AARS1, MTR, GARS1 | MEN1 2418/4885KMT2A 1195/4885ALDH1A1 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.